LIMN NASDAQ
Liminatus Pharma, Inc. Class A Common Stock
1W: -7.1%
1M: +1.6%
3M: -45.3%
YTD: -87.8%
1Y: -95.5%
$3.90
+0.15 (+4.00%)
Weekly Expected Move ±10.0%
$3
$4
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$3M
-12.4% ▼
Net Income
-$3M
-136.9% ▼
EPS (Diluted)
$-0.40
-166.7% ▼
EBITDA
-$3M
-152.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — |
| R&D Expenses | $4M | $2M | $4M | $3M |
| SG&A Expenses | $197K | $856K | $1M | $645K |
| Operating Expenses | $3M | $3M | $3M | $3M |
| Operating Income | -$3M | -$3M | -$3M | -$3M |
| Operating Margin | — | — | — | — |
| Interest Expense | $0 | $219K | $175K | $138K |
| Income Before Tax | $4M | -$3M | -$1M | -$3M |
| Tax Expense | $0 | $0 | $34K | $19K |
| Net Income | $4M | -$3M | -$1M | -$3M |
| Net Margin | — | — | — | — |
| EPS (Diluted) | $0.13 | $-0.08 | $-0.15 | $-0.40 |
| EBITDA | $4M | -$3M | -$1M | -$3M |
| Shares Outstanding | 34M | 34M | 8M | 7M |